All that glitters is not gold: a case report of a diffuse peritoneal aspergillosis.

Invasive aspergillosis is a rare disease, more frequently encountered in immunocompromised patients. We report a case of diffuse peritoneal aspergillosis. A 56-year old female with a history of recent renal transplantation was admitted with a suspicion of peritoneal carcinomatosis following a native computed tomography scan. Gray scale abdominal ultrasound showed multiple peritoneal masses. Upon performing contrast-enhanced ultrasound these masses demonstrated peripheral arterial enhancement and slow wash-out during the venous phase. The final histopathological examination confirmed a diagnosis of peritoneal aspergillosis. Gray scale ultrasonography in combination with contrast-enhanced ultrasonography is useful in the evaluation of intraabdominal masses. The procedures are of great value especially in patients with a high risk of contrastinduced nephropathy where contrast-enhanced CT or MRI are contraindicated.

[1]  J. Rello,et al.  Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes , 2015, Critical Care.

[2]  R. Sawyer,et al.  Aspergillus infections in transplant and non-transplant surgical patients. , 2014, Surgical infections.

[3]  L Barozzi,et al.  The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): Update 2011 on non-hepatic applications , 2011, Ultraschall in der Medizin.

[4]  D. Kontoyiannis,et al.  The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  C. Heussel,et al.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Guinea,et al.  Update on invasive aspergillosis: clinical and diagnostic aspects , 2006 .

[8]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[9]  Nina Singh,et al.  Aspergillus Infections in Transplant Recipients , 2005, Clinical Microbiology Reviews.

[10]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[11]  G. Maschmeyer,et al.  Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. , 2007, Drugs.

[12]  A. Bernard,et al.  Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.